Potential milestone payments could bring Intelliject’s take to $230 million.
Sanofi-aventis obtained the rights to Intelliject’s epinephrine auto-injector for the emergency treatment of anaphylaxis in the U.S. and Canada. Under the license, sanofi-aventis U.S. will be responsible for manufacturing and commercialization. Intelliject will be responsible for the ongoing development and for obtaining U.S. regulatory approval. Intelliject has retained certain co-promotion rights.
Sanofi-aventis U.S. will make an initial up-front payment of $25 million. Intelliject will also be eligible to receive development and commercial milestones of up to $205 million as well as tiered double-digit royalties on sales of any products commercialized under the license.
“This partnership marks a key milestone in our quest to make our novel epinephrine auto-injector available to the millions of patients at risk for anaphylaxis. We expect it to create significant long-term value for the company; it marks the first step on our mission to bring the same innovation and patient-centric solutions to many different therapy areas,” says Spencer Williamson, president and CEO of Intelliject.
